Diaceutics issues share options to directors and key staff

NEW YORK/BELFAST/LONDON - Diaceutics PLC (AIM:LON:DXRX), a technology and solutions provider to the pharma and biotech industry, has granted 1,886,357 share options to directors, senior management and key staff under its Employee Share Option Plan.

The options were issued Wednesday as part of the company’s long-term incentive plan outlined in its Annual Report. CEO Ryan Keeling received 271,688 options, bringing his total to 1,339,298, representing 1.58% of existing issued share capital. CFO Nick Roberts was granted 194,063 options, while Chief Data Officer Jordan Clark received 189,750.

Three other members of senior management classified as Persons Discharging Managerial Responsibilities (PDMRs) received allocations: Chief Commercial Officer Jillian Beggs (83,771), Chief People Officer Sandra Blake (86,250), and Chief Product and Marketing Officer Susanne Munksted (88,187). An additional 972,648 options were distributed among 64 other employees.

For executive directors, the options vest on a sliding scale based on Total (EPA:TTEF) Shareholder Return growth, revenue Compound Annual Growth Rate, and Adjusted EBITDA Margin during the three-year performance period starting July 22, 2025. Options for other employees vest after three years, contingent on continued employment and satisfactory performance.

The exercise price is £0.002 per share, equivalent to the nominal value of ordinary shares. Following this grant, Diaceutics has 6,211,466 outstanding share options, representing approximately 7.32% of its current issued share capital of 84,812,636.

The company’s Remuneration Committee maintains discretion to amend performance conditions after periodic reviews, considering overall company performance and shareholder experience, according to the press release statement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.